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Purpose: Genetic factors influence an individual’s risk for developing neovascular age-related macular degeneration
(AMD), a leading cause of irreversible blindness. Previous studies on the potential genetic link between AMD and vascular
endothelial growth factor (VEGF), a key regulator of angiogenesis and vascular permeability, have yielded conflicting
results. In the present case-control association study, we aimed to determine whether VEGF or its main receptor tyrosine
kinase VEGFR-2 is genetically associated with neovascular AMD.
Methods: A total of 515 Caucasian patients with neovascular AMD and 253 ethically-matched controls were genotyped
for polymorphisms in the VEGFA and VEGFR-2 genes. A tagging single nucleotide polymorphism (tSNP) approach was
employed to cover each gene plus two kilobases on each side, spanning the promoter and 3′ untranslated regions. SNPs
with a minimum allele frequency of 10% were covered by seven tSNPs in VEGFA and 20 tSNPs in VEGFR-2. Two
VEGFA SNPs previously linked with AMD, rs1413711 and rs3025039, were also analyzed.
Results: The 29 VEGFA and VEGFR-2 SNPs analyzed in our cohort demonstrated no significant association with
neovascular AMD. A single rare haplotype in the VEGFR-2 gene was associated with the presence of neovascular AMD
(p=0.034).
Conclusions: This study is the first to investigate the association of VEGFR-2 polymorphisms with AMD and evaluates
VEGFA genetic variants in the largest neovascular AMD cohort to date. Despite the angiogenic and permeability-
enhancing effects of VEGF/VEGFR-2 signaling, we found minimal evidence of a significant link between polymorphisms
in the VEGFA and VEGFR-2 genes and neovascular AMD.
Age-related macular degeneration (AMD) is a leading
cause of irreversible blindness in individuals over the age of
50  in  the  Western  world  [1].  In  addition  to  dietary  and
environmental  risk  factors,  genetics  influences  AMD
susceptibility [2]. Recently, single nucleotide polymorphisms
(SNPs) in the complement factor H (CFH) gene [3-5] and the
ARMS2/HTRA1  locus  [6,7]  have  been  strongly  linked  to
AMD. Common variants in the complement factor B (CFB)/
complement  component  2  (C2)  [8,9]  and  complement
component 3 (C3) [10-13] genes have also been associated
with presence of AMD. Vascular endothelial growth factor
(VEGF), coded for by the VEGFA gene, is a key mediator of
angiogenesis and vascular permeability. Thus, VEGF is a
logical  candidate  for  genetically  influencing  AMD
susceptibility,  based  on  its  functional  relevance  to  AMD
pathophysiology.
VEGF plays a key role in the angiogenesis, vascular
leakage,  and  inflammation  that  is  characteristic  of  the
neovascular form of advanced AMD [14]. In recent years, the
VEGF signaling pathway has been targeted for inhibition
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therapy to treat choroidal neovascularization secondary to
AMD  [15].  VEGF  regulates  angiogenesis  in  the  vascular
endothelium  through  the  high-affinity  receptor  tyrosine
kinases VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1, KDR) [16].
Of  these  two  receptors,  VEGFR-2  is  responsible  for  the
majority  of  the  angiogenic  and  permeability-enhancing
effects of VEGF [17,18]. VEGFR-1 regulates VEGF activity
in the vascular endothelium by preventing VEGF/VEGFR-2
binding [17].
A relationship between the VEGFA and VEGFR-2 genes
and  neovascular  AMD  seems  plausible,  given  the  role  of
choroidal neovascularization in the pathophysiology of late-
stage AMD and the importance of the receptor VEGFR-2 in
the  VEGF-signaling  pathways  that  modulate  angiogenesis
and vascular permeability. Several small-scale case-control
studies have reported associations between various SNPs in
VEGFA and AMD [18-21], but these results have not been
confirmed  by  subsequent  studies  [22-24].  While  a  recent
analysis  of  VEGFA  SNPs  showed  no  associations  with
neovascular AMD, it did suggest that a three-SNP VEGFA
haplotype increased the risk of neovascular AMD [25]. To our
knowledge, the potential link between VEGFR-2 and AMD
has  not  been  investigated.  In  this  study,  we  focused  on
neovascular  AMD,  as  its  positive  response  to  anti-VEGF
therapy implicates the VEGF pathway in the pathogenesis of
this AMD subtype. Using a tagging SNP (tSNP) approach in
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)a large cohort of neovascular AMD patients, we aimed to
determine  if  a  genetic  association  exists  between  the
VEGFA or VEGFR-2 genes and neovascular AMD.
METHODS
Subjects: This retrospective case-control association study
was approved by the Washington University Human Research
Protection  Office  and  the  Barnes  Retina  Institute  Study
Center. Research adhered to the tenets of the Declaration of
Helsinki  and  was  conducted  in  accordance  with  Health
Insurance Portability and Accountability Act regulations. All
participants were enrolled from the clinical offices of the
Barnes Retina Institute, and informed consent was obtained
before  participation.  Participants  were  identified  through
chart review, and only Caucasian patients with a diagnosis of
neovascular AMD were included. Controls were identified as
having no signs of AMD and were recruited from the same
locations.
A total of 768 patients were genotyped for SNPs in the
VEGFA  and  VEGFR-2  genes  using  DNA  extracted  from
mouthwash samples. Each participant provided buccal tissue
samples by expectorating into 50 ml conical tubes (Falcon;
BD  Biosciences,  San  Jose,  CA)  after  vigorously rinsing for
30 s with approximately 20 ml Scope mouthwash (Procter
& Gamble,  Cincinnati,  OH).  Genomic  DNA  was prepared
from  the  collected  buccal  cells using the Gentra Puregene
Buccal Cell Kit (Qiagen, Valencia, CA).
Tagging  single  nucleotide  polymorphism  selection:  We
employed  a  tSNP  approach  to  cover  the  VEGFA  and
VEGFR-2  genes  plus  two  kilobases  (kb)  on  each  side,
including the promoter and 3′ untranslated regions. Using
HapMap Project Build 36, we identified the SNPs in each gene
with a minimum allele frequency (MAF) of 10% [18,22]. The
minimum r2 value was set to 0.80, and genotypes for the
Centre  d’Etude  du  Polymorphisme  Humain  (CEPH)  from
Utah (CEU) population (Utah residents with ancestry from
northern  and  western  Europe)  were  used.  We  selected
VEGFA tSNPs and VEGFR-2 tSNPs covering the HapMap-
identified  SNPs  through  the  Tagger  algorithm.  Using
Sequenom MassARRAY technology (Sequenom Inc., San
Diego,  CA),  study  participants  were  genotyped  for  these
tSNPs, as well as for two additional SNPs (rs1413711 and
rs3025039) previously associated with AMD [19,20].
Data analysis: Descriptive statistics for all demographic and
clinical  variables  were  calculated,  and  comparisons  were
made using the ANOVA test for means with continuous data
(e.g., age) and the chi-square test for categorical data (e.g.,
gender).  Genotyping  data  was  loaded  into  Haploview  in
TABLE 2. GENOTYPE DISTRIBUTION FOR SINGLE NUCLEOTIDE POLYMORPHISMS IN VEGFA
SNP Genotype OR
95% CI
Unadjusted
p-value
Adjusted
  p-value
rs699947 AC 1.02 0.66 1.57 0.025 0.223
CC 1.81 1.08             3.05
rs25648 CT 1.02 0.69 1.53 0.180 1.000
TT 0.36 0.15             0.86
rs1413711 GA 0.62 0.40 0.96 0.042 0.381
AA 0.59 0.35             0.98
rs833068 GA 1.38 0.95 2.02 0.237 1.000
AA 1.17 0.65             2.15
rs2146323 CA 0.82 0.56 1.20 0.326 1.000
AA 0.82 0.48             1.40
rs3025030 GC 1.10 0.72 1.70 0.254 1.000
CC 2.88 0.76            14.69
rs3025035 CT 1.19 0.69 2.10 0.230 1.000
TT 1749 0.00              NA
rs3025039 CT 1.12 0.74 1.72 0.296 1.000
TT 2.48 0.62            13.08
rs10434 GA 0.77 0.50 1.18 0.099 0.892
AA 0.66 0.40             1.08
Genotype analysis of VEGFA   single nucleotide polymorphisms (SNPs) was performed by logistic regression, incorporating
adjustments for age and gender. Odds ratios (OR), 95% confidence intervals (CI), and p-values are reported by genotype (normal/
variant, variant/variant) for each tested SNP. Adjusted p-values have been corrected for multiple comparisons using the
Bonferroni method.
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2712linkage format to generate allele frequencies, ratios, and p
values based on a chi-square test for association of alleles
[26].  The  Hardy–Weinberg  equilibrium  test  was  used  to
confirm that genotypes fell within a standard distribution.
Genotype distributions were analyzed by logistic regression,
incorporating  adjustments  for  age  and  gender.  Haplotype
blocks encompassing the tested SNPs were defined by 95%
confidence intervals and were predicted using Haploview.
Statistics were performed with SPSS (version 17; SPSS Inc.,
Chicago,  IL).  For  all  statistical  analyses,  p<0.05  was
considered  to  be  statistically  significant,  and  multiple
comparisons were adjusted for by the Bonferroni correction.
RESULTS
Using HapMap and Tagger for tSNP selection, we identified
seven VEGFA tSNPs and 22 VEGFR-2 tSNPs to cover both
genes.  Because  two  assays  failed  design,  20  tSNPs  in
VEGFR-2 were selected for genotyping. The two failed tSNPs
correlated poorly with other SNPs, and alternative SNPs could
not be chosen. The 20 genotyped tSNPs in VEGFR-2 had a
mean r2 of 0.97 and captured 44 of the 46 SNPs with a MAF
greater than 10%.
A total of 515 Caucasian patients with neovascular AMD
and 253 ethnically-matched controls were genotyped for this
study. Cases and controls had mean ages of 79.2 and 69.3
years, respectively (p<0.001). The case cohort consisted of a
lower percentage of males (33.6%) than did the control cohort
(43.9%;  p=0.005).  Adjustments  for  age  and  gender  were
incorporated in the genotype analysis of both VEGFA and
VEGFR-2. All analyzed SNPs conformed to Hardy–Weinberg
equilibrium in both the case and control populations. Allele
distributions did not differ significantly between cases and
controls  for  any  of  the  nine  VEGFA  SNPs  (Table  1).
According   to   the   genotype   distribution   for  these  SNPs
(Table 2), one tSNP ( rs699947  ) and  one  SNP  previously
associated with AMD (rs1413711)  demonstrated  significant
uncorrected  p values,  but  no significant  association was
found  for  any  VEGFA  SNP  after  correcting  for  multiple
comparisons. Allele distributions for the 20  VEGFR-2 tSNPs
showed significant uncorrected  p  values  for   three   tSNPs,
but  none  remained significant after correcting for multiple
comparisons (Table 3). No VEGFR-2  tSNPs were associated
with neovascular AMD by genotype distribution (Table 4).
Linkage disequilibrium-based haplotypes were defined
for  the  VEGFA  and  VEGFR-2  SNPs,  resulting  in  two
haplotype blocks for VEGFA (Figure 1) and five haplotype
blocks  for  VEGFR-2  (Figure  2).  Haplotype  analysis
demonstrated no VEGFA haplotypes to be associated with
neovascular AMD (Table 5) but did reveal a mild association
of the rarest haplotype (TTT) in VEGFR-2 haplotype block 3
with neovascular AMD (p=0.034, Table 6).
DISCUSSION
We  analyzed  nine  SNPs  in  VEGFA  and  20  tSNPs  in
VEGFR-2 using a tSNP approach designed to cover both
genes.  The  results  of  this  study  show  little  evidence  of
association  with  neovascular  AMD  in  our  cohort  of  515
Caucasian patients.
Previous investigation of VEGFA and AMD has yielded
conflicting results. A few smaller-scale case-control studies
have reported significant associations for various SNPs in
VEGFA  [18-21],  but  the  validity  of  these  results  remains
unconfirmed  [22-24].  The  only  one  of  these  studies  to
investigate a large neovascular AMD cohort (n=342) using a
comprehensive  tSNP  approach  found  no  link  between
VEGFA tSNPs and development of neovascular AMD [22].
More recently, a single haplotype was shown to be weakly
associated  with  neovascular  AMD  in  a  moderately-sized
cohort (n=211), although no associations were found with
individual VEGFA SNPs [25]. In the present study, we found
no association between neovascular AMD and VEGFA SNPs
or  haplotypes.  These  discrepant  findings  may  be  due  to
inadequate sample size in the early studies or to the ethnic
composition  of  study  populations.  Results  could  also  be
biased by genotyping error or confounding effects due to
statistically significant variables such as age, gender, or other
SNPs known to be associated with AMD. As a whole, the
studies  performed  to  date  provide  little  evidence  that
VEGFA polymorphisms exert any significant influence on
risk of neovascular AMD.
This  is  the  first  study  to  investigate  the  relationship
between variants in VEGFR-2 and AMD. One of two receptor
tyrosine  kinases  involved  in  VEGF  signaling  pathways,
VEGFR-2  mediates  the  majority  of  the  angiogenic  and
permeability-enhancing  effects  of  VEGF  [17].  The
importance of VEGFR-2 in developmental angiogenesis and
hematopoiesis, as demonstrated by the abnormal vasculature
of VEGFR-2 knockout mice [27], suggests a link between the
VEGF/VEGFR-2  pathway  and  retinal  pathology.  While
VEGF and its receptors play a key role in tumor angiogenesis
and  other  pathological  conditions  [14,16,28,29],  a  limited
number of gene association studies have been performed for
VEGF  receptor  genes.  Recently,  polymorphisms  in
VEGFR-1 and VEGFR-2 were reported to be associated with
sarcoidosis, an inflammatory condition with a hypothesized
antigenic stimulus [30]. Variants in VEGFR-2 have also been
linked  with  heart  disease  and  may  influence  the  risk  of
developing breast cancer [31-33]. In our large neovascular
AMD cohort, no associations were found for any VEGFR-2
tSNPs by allele or genotype analysis. Haplotype analysis,
however,  did  show  a  single  rare  haplotype  to  be  mildly
associated with AMD.
This study is limited by its retrospective design, which
did  not  allow  for  assessment  of  the  predictive  value  of
VEGFA and VEGFR-2. However, in light of our negative
findings,  it  is  doubtful  that  a  prospective  study  would
contribute significantly to our knowledge base. This study was
designed to investigate common polymorphisms that might
Molecular Vision 2009; 15:2710-2719 <http://www.molvis.org/molvis/v15/a287> © 2009 Molecular Vision
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PTABLE 4. GENOTYPE DISTRIBUTION FOR TAGGING SINGLE NUCLEOTIDE POLYMORPHISMS IN VEGFR-2
SNP Genotype OR
95% CI Unadjusted
   p-value
Adjusted
  p-value
rs7691507 TC 1.04 0.71 1.55 0.602 1.000
  CC 1.37 0.53 3.91    
rs12642307 TC 1.11 0.77 1.62 0.306 1.000
  CC 1.40 0.74 2.76    
rs2125489 CT 0.83 0.54 1.29 0.482 1.000
  TT 1.23 0.19 24.17    
rs1531289 GA 1.11 0.76 1.63 0.360 1.000
  AA 1.34 0.70 2.63    
rs17709898 AG 0.77 0.52 1.13 0.068 1.000
  GG 0.63 0.37 1.09    
rs12505758 TC 0.91 0.57 1.44 0.548 1.000
  CC 5.68 0.99 107.98    
rs13109660 GA 1.09 0.75 1.58 0.271 1.000
  AA 1.47 0.80 2.78    
rs1870377 TA 0.96 0.66 1.42 0.527 1.000
  AA 0.76 0.37 1.56    
rs7654599 TC 0.72 0.48 1.08 0.672 1.000
  CC 1.00 0.58 1.76    
rs17085326 CT 0.85 0.51 1.43 0.665 1.000
  TT 1.21 0.23 9.16    
rs2034965 GA 1.13 0.77 1.65 0.506 1.000
  AA 1.18 0.55 2.63    
rs10020464 CT 1.24 0.85 1.81 0.516 1.000
  TT 1.02 0.55 1.93    
rs2305948 CT 0.85 0.53 1.39 0.250 1.000
  TT 0.43 0.10 1.80    
rs7692791 TC 1.23 0.80 1.88 0.834 1.000
  CC 0.94 0.58 1.53    
rs2305949 CT 1.05 0.71 1.57 0.605 1.000
  TT 0.62 0.27 1.46    
rs6837735 CT 1.22 0.82 1.82 0.209 1.000
  TT 1.65 0.57 5.47    
rs1531290 AG 0.90 0.58 1.37 0.605 1.000
  GG 1.15 0.70 1.91    
rs12502008 GT 0.86 0.59 1.26 0.449 1.000
  TT 0.85 0.47 1.58    
rs7667298 TC 0.90 0.57 1.41 0.259 1.000
  CC 0.76 0.46 1.24    
rs2239702 GA 1.15 0.79 1.66 0.465 1.000
  AA 1.17 0.57 2.52    
Genotype analysis of VEGFR-2  tagging single nucleotide polymorphisms (tSNPs) was performed by logistic regression,
incorporating adjustments for age and gender. Odds ratios (OR), 95% confidence intervals (CI), and p-values are reported by
genotype (normal/variant, variant/variant) for each tested tSNP. Adjusted p-values have been corrected for multiple comparisons
using the Bonferroni method.
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be associated with neovascular AMD risk, and it remains
possible that rare variants with MAFs less than 10% could
play a role in neovascular AMD development. Due to tSNP
assay failure, two of the 46 VEGFR-2 SNPs with a MAF
greater  than  10%  were  poorly  tagged.  The  20  successful
VEGFR-2 tSNPs in our study covered the polymorphisms
previously  found  to  be  associated  with  human  diseases:
rs1870377, rs2071559 (covered by rs7667298), rs2125489,
rs2305948, rs7667298, and rs7691507 [31-34].
In  summary,  this  study  is  the  first  to  investigate  the
association  of  VEGFR-2  polymorphisms  with  AMD  and
evaluates VEGFA genetic variants in the largest neovascular
AMD cohort to date. Although both VEGF and its receptors
have been implicated in the pathophysiology of diseases such
as AMD, we found minimal evidence that polymorphisms in
VEGFA  and  VEGFR-2  contribute  significantly  to  risk  of
neovascular AMD.
Figure 1. Linkage disequilibrium map of
VEGFA  single  nucleotide
polymorphisms. Two haplotype blocks
(bolded)  were  identified  for  the  nine
single  nucleotide  polymorphisms
(SNPs)  in  the  vascular  endothelial
growth factor (VEGFA) gene. A linkage
disequilibrium map of these haplotype
blocks was generated using Haploview.
Length  of  each  block  is  provided  in
kilobases  (kb),  and  pairwise  linkage
disequilibrium  (D’)  is  given  for  each
SNP  combination.  Dark  red  shading
denotes D’ values greater than 0.80, and
empty squares indicate D’ values of 1.0.
Figure 2. Linkage disequilibrium map of
VEGFR-2  tagging  single  nucleotide
polymorphisms. Five haplotype blocks
were identified for the 20 tagging single
nucleotide  polymorphisms  (tSNPs)  in
the vascular endothelial growth factor
receptor-2 (VEGFR-2) gene. A linkage
disequilibrium map of these haplotype
blocks was generated using Haploview.
Length  of  each  block  is  provided  in
kilobases  (kb),  and  pairwise  linkage
disequilibrium  (D’)  is  given  for  each
SNP  combination.  Dark  red  shading
denotes D’ values greater than 0.80, and
empty squares indicate D’ values of 1.0.Molecular Vision 2009; 15:2710-2719 <http://www.molvis.org/molvis/v15/a287> © 2009 Molecular Vision
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TABLE 5. HAPLOTYPE ANALYSIS OF VEGFA
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5 Frequency in
cases
Frequency in
controls
p-value
Block 1
rs699947 rs25648 rs1413711 rs833068 rs2146323
C C G A C 0.329 0.292 0.139
A T A G A 0.176 0.193 0.428
C C G G C 0.177 0.166 0.592
A C A G A 0.169 0.171 0.910
A C A G C 0.133 0.153 0.282
Block 2
rs3025039 rs10434
C A 0.470 0.486 0.549
C G 0.397 0.383 0.606
T G 0.133 0.130 0.889
Two haplotype blocks were identified for the tested single nucleotide polymorphisms (SNPs) in VEGFA   using Haploview.
Haplotype frequencies in neovascular age-related macular degeneration patients (cases) and participants without age-related
macular degeneration (controls) are reported with corresponding p-values. Haplotypes with frequencies above 0.01 are included
in the table.
TABLE 6. HAPLOTYPE ANALYSIS OF VEGFR-2
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5 Frequency in
cases
Frequency in
controls
p-value
Block 1
rs1531289 rs17709898 rs12505758 rs13109660 rs1870377
G A T A T 0.351 0.304 0.066
G G T G A 0.217 0.257 0.087
A A T G T 0.182 0.182 0.992
G G T G T 0.105 0.123 0.302
A A C G T 0.113 0.102 0.514
G G T A T 0.015 0.008 0.248
Block 2
rs7654599 rs17085326
T C 0.516 0.510 0.835
C C 0.406 0.415 0.731
T T 0.079 0.075 0.807
Block 3
rs10020464 rs2305948 rs7692791
C C C 0.463 0.455 0.772
C C T 0.246 0.248 0.910
T C T 0.196 0.170 0.230
T T T 0.086 0.121 0.034
Block 4
rs2305949 rs6837735
C C 0.614 0.623 0.735
T C 0.201 0.219 0.403
C T 0.185 0.158 0.187
Block 5
rs12502008 rs7667298 rs2239702
T C G 0.357 0.356 0.953
G T A 0.255 0.249 0.789
G T G 0.217 0.198 0.394
G C G 0.171 0.198 0.199
Five haplotype blocks were identified for the tagging single nucleotide polymorphisms (tSNPs) in VEGFR-2   using Haploview.
Haplotype frequencies in neovascular age-related macular degeneration patients (cases) and participants without age-related
macular degeneration (controls) are reported with corresponding p-values. Haplotypes with frequencies above 0.01 are included
in the table.Molecular Vision 2009; 15:2710-2719 <http://www.molvis.org/molvis/v15/a287> © 2009 Molecular Vision
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